No Data
No Data
Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Raises Target Price to $6
12 Health Care Stocks Moving In Friday's Intraday Session
$AKBA Stock Is up 28% Today. Here's What We See in Our Data.
Akebia Therapeutics Price Target Raised to $6.00/Share From $4.00 by Piper Sandler
Akebia Therapeutics Is Maintained at Overweight by Piper Sandler
Unlock the Full List